ALN-ANG3 vs NNC0491-6075
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: ANGPTL3 · full Atherosclerotic Cardiovascular Disease pipeline
ALN-ANG3
Developed by Regeneron Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT06452771 (registry estimate)
No aligned efficacy figure on record for this race.
NNC0491-6075
Developed by Novo Nordisk
NCT05979428 · Phase 1 · completed
Participants were randomly assigned to drug or placebo under quadruple-blind conditions across ascending-dose cohorts, a sound early-safety design, but the primary measure was the number of adverse events rather than a clinical or lipid outcome, and results have not yet been reported. Its registered primary outcome on ClinicalTrials.gov is "Part A (SAD): Number of treatment emergent adverse events (TEAEs)" (with 2 other safety or dose-finding measures). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
No aligned efficacy figure on record for this race.
Results for Atherosclerotic Cardiovascular Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | ALN-ANG3 | NNC0491-6075 |
|---|---|---|
| LDL-C, % change | —Not reported | —Not reported |
| Non-HDL-C, % change | —Not reported | —Not reported |
| ApoB, % change | —Not reported | —Not reported |
| Lp(a), % change | —Not reported | —Not reported |
| 3-point MACE (% with event) | —Not reported | —Not reported |
LDL-C, % change
- ALN-ANG3
- —Not reported
- NNC0491-6075
- —Not reported
Non-HDL-C, % change
- ALN-ANG3
- —Not reported
- NNC0491-6075
- —Not reported
ApoB, % change
- ALN-ANG3
- —Not reported
- NNC0491-6075
- —Not reported
Lp(a), % change
- ALN-ANG3
- —Not reported
- NNC0491-6075
- —Not reported
3-point MACE (% with event)
- ALN-ANG3
- —Not reported
- NNC0491-6075
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
ALN-ANG3: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.
NNC0491-6075: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ALN-ANG3's landscape · NNC0491-6075's landscape